New hope for Hard-to-Treat cancers: targeted drug afatinib tested in Genetic-Mutation patients
NCT ID NCT06385483
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 33 times
Summary
This study tests the drug afatinib in 19 patients with advanced solid tumors or lymphomas that have a specific EGFR gene mutation and have stopped responding to standard treatments. Afatinib works by blocking the mutated EGFR signal that tells cancer cells to grow. The goal is to see if the drug can shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.